Stock Groups

2 Stocks to Avoid on Pfizer’s Announcement of a Successful Covid Antiviral Pill -Breaking

by Mike Robinson

[ad_1]

© Reuters 2 Stocks to Avoid on Pfizer’s Announcement of a Successful Covid Antiviral Pill

With Pfizer’s (PFE) COVID-19 antiviral pill getting significant attention, its competitors such as Moderna (NASDAQ: Novavax They are falling behind (NASDAQ:). MRNA, NVAX are losing ground. The colder weather is making people more worried about possible resurgences of cases. It was made public on November 5, and investors were positive about it. Pfizer Inc.’s (NYSE:) COVID-19 pill, when used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89%.

However, it might not go well for the other COVID-19 vaccine developers or manufacturers. Geoffrey C. Porges, MBBS, director of therapeutics research and a senior research analyst at SVB Leerink, said on November 5, “This result is clearly good news for Pfizer shareholders, and initially negative news for the developers of other COVID antivirals.”

PFE is likely to lead the COVID-19 Antiviral Race. Therefore, you might be smart to steer clear of Moderna, Inc., Novavax, Inc., and Novavax, Inc.

Continue reading on StockNews

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this website’s data including quotes, charts, or buy/sell signal information. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]